106 CHAPTER 4 REFERENCES 1 Fisher, R. I., Rosenberg, S. A. & Fyfe, G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 6, S55-S57 (2000). 2 McDermott, D. F. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 23, 133-141, doi:10.1200/Jco.2005.03.206 (2005). 3 Motzer, R. J. et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. Journal of Clinical Oncology 18, 2972-2980, doi:Doi 10.1200/ Jco.2000.18.16.2972 (2000). 4 Negrier, S. et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. New Engl J Med 338, 1272-1278, doi:Doi 10.1056/ Nejm199804303381805 (1998). 5 Hutson, T. E. et al. Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial. Clin Genitourin Canc 15, 72-76, doi:10.1016/j. clgc.2016.05.008 (2017). 6 Konishi, S. et al. Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis. Med Oncol 36, doi:ARTN 6 10.1007/s12032-018-1231-3 (2019). 7 Motzer, R. J. et al. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma. New Engl J Med 369, 722-731, doi:10.1056/NEJMoa1303989 (2013). 8 Schmidinger, M. et al. Prospective Observational Study of Pazopanib in Patients with Advanced Renal Cell Carcinoma (PRINCIPAL Study). Oncologist 24, 491-497, doi:10.1634/theoncologist.2018-0787 (2019). 9 Rini, B. I. et al. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Engl J Med 380, 1116-1127, doi:10.1056/NEJMoa1816714 (2019). 10 Motzer, R. J. et al. Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New Engl J Med 380, 1103-1115, doi:10.1056/NEJMoa1816047 (2019). 11 Klaeger, S. et al. The target landscape of clinical kinase drugs. Science 358, doi:ARTN eaan4368 10.1126/science.aan4368 (2017). 12 Motzer, R. et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 20, 1370-1385, doi:10.1016/S1470-2045(19)30413-9 (2019). 13 Motzer, R. J. et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology 27, 3584-3590, doi:10.1200/Jco.2008.20.1293 (2009). 14 Gore, M. E. et al. Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma. Brit J Cancer 113, 12-19, doi:10.1038/bjc.2015.196 (2015).
RkJQdWJsaXNoZXIy MTk4NDMw